 |
 Play Video: The Importance of Insider Buying
|
|
|
| Date | Insider | Price | Amount |
|---|
12-16-2021
Insider Buy |
Chirag K. Patel
President & Co-CEO |
$4.17
CAGR »
|
$625,500.00
150,000 shares |
12-16-2021
Insider Buy |
Chintu Patel
Co-CEO |
$4.17
CAGR »
|
$625,500.00
150,000 shares |
5-19-2020
Insider Buy |
John Kiely
Director |
$4.40
CAGR »
|
$44,000.00
10,000 shares |
5-15-2020
Insider Buy |
Jeffrey P. George
Director |
$4.16
CAGR »
|
$99,049.60
23,810 shares |
3-10-2020
Insider Buy |
Chirag K. Patel
President, Co-CEO & Director |
$3.09
CAGR »
|
$309,000.00
100,000 shares |
3-10-2020
Insider Buy |
Chintu Patel
Co-CEO and Director |
$3.09
CAGR »
|
$309,000.00
100,000 shares |
3-4-2020
Insider Buy |
Chintu Patel
Co-CEO and Director |
$3.90
CAGR »
|
$974,941.89
250,000 shares |
3-4-2020
Insider Buy |
Chirag K. Patel
President, Co-CEO & Director |
$3.90
CAGR »
|
$974,958.01
250,000 shares |
3-1-2020
Insider Buy |
Joseph Todisco
SVP, Specialty Commercial |
$3.62
CAGR »
|
$144,800.00
40,000 shares |
8-28-2019
Insider Buy |
Ted C. Nark
Director |
$2.39
CAGR »
|
$119,500.00
50,000 shares |
8-16-2019
Insider Buy |
Pradeep Bhadauria
SVP, Chief Scientific Officer |
$2.41
CAGR »
|
$72,300.00
30,000 shares |
8-6-2019
Insider Buy |
International Ltd Fosun
>10% Owner |
$2.91
CAGR »
|
$951,570.00
327,000 shares |
8-7-2019
Insider Buy |
Andrew S. Boyer
Exec VP, Comm Optns |
$2.89
CAGR »
|
$192,664.74
66,666 shares |
8-5-2019
Insider Buy |
International Ltd Fosun
>10% Owner |
$3.04
CAGR »
|
$4,992,592.00
1,642,300 shares |
5-15-2019
Insider Buy |
Pradeep Bhadauria
SVP, Chief Scientific Officer |
$8.48
CAGR »
|
$59,360.00
7,000 shares |
5-13-2019
Insider Buy |
Andrew S. Boyer
Exec VP, Comm Optns |
$9.46
CAGR »
|
$179,740.00
19,000 shares |
5-13-2019
Insider Buy |
Joseph Todisco
SVP, Specialty Commercial |
$9.88
CAGR »
|
$148,200.00
15,000 shares |
3-12-2019
Insider Buy |
Robert A. Stewart
President and CEO |
$11.92
CAGR »
|
$202,640.00
17,000 shares |
3-12-2019
Insider Buy |
Paul Bisaro
Executive Chairman |
$11.97
CAGR »
|
$203,490.00
17,000 shares |
Also See: Institutional Holders of AMRX
Also See: SEC filings
Below we present the annualized performance delivered by Amneal Pharmaceuticals stock since 12-16-2021 (the date of the most recent
insider purchase). The performance of the investment from the time Amneal Pharmaceuticals insider buying occurred is the ultimate
test of whether insiders were right about AMRX being a good buy.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
12/17/2021 |
|
| End date: |
04/26/2024 |
|
| Start price/share: |
$4.27 |
|
| End price/share: |
$5.87 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
37.47% |
|
| Average Annual Total Return: |
14.46% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$13,746.68 |
|
| Years: |
2.36 |
|
Amneal Pharmaceuticals Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.),
and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these
categories, but instead file their holdings quarterly on the latest form 13F filings.
While recent Amneal Pharmaceuticals insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
Also See: Funds Holding AMRX
|
|
Free AMRX Email Alerts:
